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Pityriasis rubra pilaris (PRP) is a rare group of hyperkeratotic, papulosquamous disease that can be
acquired or inherited. There have been reported cases of rheumatologic associations, mainly arthritis
and dermatomyositis. In this review article, we will explore the clinical presentation and classiﬁcation,
rheumatologic associations and treatment modalities of PRP. In addition, we will also report a case of
PRP with seronegative arthritis.
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CASE REPORT
A 50-year-old East Indian male with a 2-year history of
nonspeciﬁc knee arthritis presented to his primary care
doctor with a new scaly and pruritic rash. It began on the
extensor surfaces of the elbow and bilaterally spread onto
the forearms. Similar lesions began to appear over the
scalp, trunk, axilla and knee. His nails became thickened
and hyperpigmented. The patient was diagnosed with
psoriasis. With the appearance of the lesions, his knee pain
intensiﬁed, especially when ascending the stairs. The pain
would awaken him at night. During this period, he had
stiffeningofhisextremities.Besidesfatigue,hedeniedany
recent acute illnesses, constitutional symptoms, and
mucocutaneous or ocular lesions. His past medical history
includedhypothyroidismandseasonalallergies.Hedenied
food,drug andenvironmental allergies.Hismedicationlist
at presentation included levothyroxine and glucosamine
and chondroitin. He smoked tobacco occasionally and
owned a cat. He had not traveled outside the country
recently. His mother had nonspeciﬁc arthritis. On physical
examination, his vitals were normal. There were no
lymphadenopathy, oral lesions and hepatosplenomegaly.
Neither joint deformity nor synovitis was appreciated.
He had tenderness of the right knee on palpation with mild
patellar laxity. He had multiple sharply demarcated red–
orange scaly plaques over the extensor surfaces of the
forearms,axillae,kneesandtrunk.Theplaqueswerenearly
conﬂuent on his trunk with the exception of islands of
normal skin. The skin of his palms was thick and dry.
Bilaterally, his second and third ﬁngernails were
hyperkeratotic with pitting and hyperpigmentation.
X-rays of the hands and knees were normal. Complete
blood count,complete metabolicpanelandurinalysiswere
normal. The erythrocyte sedimentary rate was 15;
antinuclear antibody was 1:160 with a nucleolar pattern.
Thyroid stimulating hormone, immunoglobulin and
complement levels were normal. Rheumatoid factor,
hepatitis panel and RPR were negative.He did not respond
totheconventionalpsoriatictreatmentwithultravioletlight
therapy UVA and UVB. Eventually, a punch biopsy was
performed,anda diagnosisofpityriasis rubrapilaris(PRP)
wasmade.Thepatientwasplaced onmethotrexatetherapy
and his arthritis and skin lesions subsequently resolved.
INTRODUCTION
PRP is a rare group of hyperkeratotic, papulosquamous
disease that can be acquired or inherited. It was ﬁrst
describedbyAlaudiusTarralin1828,andDevergienamedit
“pityriasispilaris”in1856(Grifﬁths,1976;Foxetal.,1985).
In 1889, Besnier renamed the disease to PRP (Grifﬁths,
1976). This rare skin disorder occurs in all races, affects
both sexes equally, and has been reported world wide
(Grifﬁths, 1980). The incidence of patients presenting to
dermatology clinics in the United States has been
reported to be 1 in 3500–5000 patients (Rinker and
Shenefelt, 2003). PRP occurs in a bimodal distribution,
peaking in the ﬁrst and then the ﬁfth decades (Grifﬁths,
1980). Although there are hereditary forms, most cases are
acquired. It is commonly confused with other papulosqua-
mous and erythrodermic disorders, particularly psoriasis.
Although the etiology is unknown, there has been recent
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dysregulation where there is an abnormal response to
antigenictriggers(AlbertandMackool,1999;Betlochetal.,
2001; Behr et al., 2002). However, hypothesis has ranged
from vitamin A deﬁciency to absence of retinol-binding
protein. Interestingly, PRP has been associated with
malignancy, autoimmune diseases, trauma and infections,
particularly human immunodeﬁciency virus (HIV). Besides
the rheumatologic association, several of the autoimmune
processes associated with PRP include myasthenia gravis,
hypothyroidism and celiac sprue (Albert and Mackool,
1999). Histological features of PRP are nonspeciﬁc and
diagnosis cannot be made solely on histology (Fox et al.,
1985; Cohen and Prystowsky, 1989). However, it helps
to exclude disorders with similar characteristics. The
differential diagnosis is frequently papulosquamous and
erythroidermicdisorders (TableI). The nonspeciﬁc features
include hyperkeratosis, alternating orthokeratosis and
parakeratosis in vertical and horizontal directions, irregular
acanthosis, a conﬂuent granular layer, and perivascular
lymphocyticdermalinﬁltrate(CohenandPrystowsky,1989;
Albertand Mackool, 1999; Behr etal., 2002). An important
distinguishingfeatureisacantholysiswithfocalacantholytic
dyskeratosis (Albert and Mackool, 1999). It has been
reported that patients with PRP are negative for IgG, IgA,
IgM and C3 direct immunoﬂuorescence tests (Albert and
Mackool, 1999). Radioimmunoassay of PRR scales
contained small amounts of leukotriene B4,C 3a,C 4a and
C5a, which is in the normal range of noninﬂammatory skin
(Albert and Mackool, 1999). There has been a report of one
patient with hypogammaglobulinemia and another patient
withactivatedTsuppressorcellsandimpairedThelpercells
(Bonomo et al., 1997; Albert and Mackool, 1999). In this
review article, we will explore the clinical presentation and
classiﬁcation, rheumatologic associations and treatment
modalities of PRP.
CLINICAL PRESENTATION AND
CLASSIFICATION
The widely accepted classiﬁcation of PRP was proposed by
Grifﬁths (1980) (Table II). Grifﬁth established ﬁve types of
PRP based on clinical features, age of onset, and prognosis.
Recently, a sixth class was proposed to acknowledge the
HIV-associated type of PRP (Miralles et al., 1995). PRP in
adults typically spreads in a cephalad to caudal direction,
whereas in children it is opposite (Albert and Mackool,
1999). Juvenile types have a tendency to relapse. Systemic
symptoms, such as malaise, fatigue, fever and chills can
accompany PRP (Rinker and Shenefelt, 2003).
The classic description of PRP found in the literature is
of type I PRP. Type I, classical adult PRP, is the most
common form where adults are afﬂicted. As Grifﬁth
describes, the elementary lesion is follicular hyperker-
atosis (Grifﬁths, 1976). Progressive erythroderma devel-
ops due to follicular hyperkeratosis. Perifollicular
erythema becomes conﬂuent with the development of
scales. Often there are patches of normal skin inter-
dispersed among the lesions, known as “islands of
sparing”. The palm and soles become hyperkeratotic and
develop an orange hue, which is often very painful and
disabling when ﬁssures develop. It is common to ﬁnd
that the dorsal phalanges and extensor aspects of the wrist
and thighs will have follicular hyperkertatoic plugs with a
consistency of a nutmeg grater. Nail changes are also
frequent, consisting of yellow–brown discolorations with
splinter hemorrhages and nail plate thickening. With
severe disease where there is prolonged facial erythro-
derma, ectropions can develop.
Type II, atypical adult onset PRP, affects about ﬁve
percent of the patients (Grifﬁths, 1980). It is atypical
because it can last for more than 20 years. In addition to
chronicity, its clinical feature is different from type I by
the presence of ichtyosiform scale located on the lower
extremities. Alopecia is common. Eczematous changes
of the skin are also characteristic. The hyperkeratosis of
the palms and soles are more coarse and lamellated.
TABLE I Differential diagnosis of pityriasis rubra pilaris (Grifﬁths,
1980; Fox et al., 1985; Caplan et al., 1997; Albert and Mackool, 1999)
† Cutaneous T cell lymphoma
† Dermatomyositis
† Dermatophytosis
† Eczematous dermatitis
† Erythrokeratoderma variabilis
† Erythrokeratoderma Variabilis
† Follicular eczema
† Follicular ichthyosis
† Generalized hypersensitivity reaction
† Lichen Planopilarus
† Mycosis Fungoides
† Parasoriasis
† Psoriasis
† Seborrheic dermatitis
† Secondary syphilis
† Subacute cutaneous lupus erythematosus
† Vitamin A deﬁciency
TABLE II Modiﬁed Grifﬁth PRP classiﬁcation (Grifﬁths, 1980; Miralles and Nunez, 1996; Misery et al., 1996, Albert and Mackool, 1999)
Type Name Incidence (%) Distribution Prognosis (% resolution in 3 years) Comments
I Classic adult 55 Generalized 81 Most clear in 3 years
II Atypical adult 5 Generalized 20 Most are chronic
III Classical juvenile 10 Generalized 16 Most clear in 1 year
IV Circumscribed juvenile 25 Localized 32
V Atypical juvenile 5 Generalized 0 Chronic
VI HIV-associated Needs more evaluation Generalized Needs more evaluation
H. CHAN AND S. NAGUWA 58Type III, classical juvenile PRP, is type I PRP
occurring in children, usually during the ﬁrst years of
life. Type IV, circumscribed juvenile PRP, is a localized
form of PRP, occurring mainly on the elbows, knees
and over bony prominences. Type V, atypical juvenile
PRP, is a chronic disease and includes most familial
forms of PRP.
There has been recognition of type VI, which occurs in
established HIV disease presenting with new onset PRP. It
is characterized by the development of nodulocycstic and
lichen spinulosus lesions (Miralles et al., 1995; Misery
et al., 1996). Typically, HIV-associated PRP is refractory
to treatment.
RHEUMATOLOGIC ASSOCIATIONS
Rheumatologic association of PRP is not well deﬁned.
Large trials to establish a clear relationship is extremely
difﬁcult because PRP is such a rare disease. However,
there has been citing of case reports in the literature of
PRP associated with arthritis and myositis, speciﬁcally
dermatomyositis.
PRP association with arthritis was ﬁrst reported in 1936
(Lister et al., 1997). Between 1973 and 2002, there have
been seven case reports describing a temporal relationship
of onset of arthritis and PRP (Table III) (Aguilar et al.,
1973; Duke et al., 1987; Fiallo et al., 1996; Lister et al.,
1997; Conaghan et al., 1999; Behr et al., 2002; Nakafusa
et al., 2002). With our report, this will make it the eighth
case. Acro-osteolysis has been frequently reported. Four
cases have reported that the arthritis preceded the rash
whereas three reported the rash to precede the arthritis,
and one case reported both to have started at the same
time. Treatment for PRP and arthritis varied between
authors (Table IV). Treatment of PRP does not guarantee
successful treatment of arthritis and vice versa.
Interestingly, ﬁve out of the eight cases have been
associated with seronegative arthritis and only one was
rheumatoidfactorpositive.Thestatusoftheothertwocases
is unknown. Seronegative arthritis is a heterogeneous class
of inﬂammatory arthritis that is deﬁned by a negative
rheumatoid factor test. The diseases classiﬁed as seronega-
tive arthritides include psoriatic arthritis, ankylosing
spondylitis, Bechet’s syndrome, and Reiter’s disease. In the
cases of PRP associated seronegative arthritis, it has been
TABLE III Case reports of PRP associated arthritis (Aguilar et al., 1973; Duke et al., 1987; Fiallo et al., 1996; Lister et al., 1997; Conaghan et al.,
1999; Nakafusa et al., 2002; Behr et al., 2002)
Case
reports Year reported Age Sex Rheumatoid factor Antinuclear antibody HLA-B27 Arthritic sites
Aguilar et al. 1973 62 M Unknown Unknown
(LE test was
negative)
Unknown Feet, eventual ﬁngers
Duke et al. 1987 18 M Unknown Unknown Unknown Fingers
Fiallo et al. 1996 19 M Negative Negative Positive Wrist, knees, ankles
Lister et al. 1997 21 F Negative Positive Unknown Neck, ﬁngers, knees, ankles
Conaghan et al. 1999 25 M Negative Negative Negative Shoulders, knees
Behr et al. 2002 12 M Negative Negative Unknown Wrists, ﬁngers
Nakafusa et al. 2002 53 M Positive Negative Negative Neck, shoulders, elbows
Chan et al. 2003 50 M Negative Positive Unknown Knees
TABLE IV Treatment modalities of PRP and arthritis (Aguilar et al., 1973; Duke et al., 1987; Fiallo et al., 1996; Lister et al., 1997; Conaghan et al.,
1999; Behr et al., 2002; Nakafusa et al., 2002)
Case reports
PRP treatment
modalities
Arthritis treatment
modalities
Failed
treatments
Aguilar et al. Vitamin A, Prednisone Chloroquine, Asprin, Prednisolone
Duke et al. Unknown Unknown
Fiallo et al. Etretinate Etretinate
Lister et al. Betamethasone ointment Methotrexate
Conaghan et al. Liarozole Anti-tumor necrosis
factor immunotherapy
Etretinate, psoralen ultraviolet A,
hydroxyurea, methortrexate,
cyclosporine A, prednisolone,
sulfasalzaine, subcutaneous
interferon
alpha, intravenous gamma globulin,
azathioprine, isotretinoin,
acitretin
Behr et al. Methotrexate and low dose acitretin Methotrexate and low dose acitretin Patient was initially on etretinate and
responded well but has increased the
dose without consultation and suffered toxicities
Nakafusa et al. Vitamin D3 ointment Bucillamine and prednisolone
Chan et al. Methotrexate Methotrexate
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mechanism that occurs in psoriatic arthritis given the close
resemblance of PRP to psoriasis. Still, the pathophysio-
logical relationship between psoriasis and seronegative
arthritis is not well established.
It is well reported in the literature of the connection
between myositis and PRP, speciﬁcally dermatomyositis.
Dermatomyositis is an inﬂammatory myopathy of the
proximal muscles with skin involvement. The skin
involvement includes the classic ﬁndings of heliotrope
rash, a purplish rash over the eyelid, Gottron papules, a
scaly rash found over the knuckles of the hands, shawl
sign, erythema over the shoulder areas exposed to the sun
representing sun sensitivity. Dermatomyositis can be
associated with internal malignancies.
Dermatomyositis with PRP is known as type
Wong variant dermatomyositis, named after Wong who
describedalargeseriesofpatients fromHongKongin1969
(Requenaetal., 1997; Lupton etal., 2000). However, it was
believedthatthatPRPasamanifestationofdermatomyositis
may have been reported as early as 1953 by O’Leary
who did not describe or illustrate the histopathological
ﬁndings (Requena et al., 1997; Lupton et al.,2 0 0 0 ) .
TREATMENT
There are many different regimens to treat PRP. Fox et al.
found over twenty different agents that have been used to
treat PRP (Fox et al., 1985). Many of these treatments had
only variable or isolated success. As a result, no single
agent is found to be reliably effective. It is difﬁcult to treat
a disorder when the etiology is unknown. Historically,
there has been favorable response to vitamin A,
systemically or topically. Unfortunately, the large oral
doses required for effective treatment usually cause toxic
side effects. The use of stanozolol is an attempt to increase
circulating levels of retinol binding protein in order to
increase tissue delivery of retinol (Cohen and Prystowsky,
1989). The androgenic side effects make it less desirable
for women to use. To avoid the toxicity of vitamin A,
synthetic vitamin A therapy has become popular with
favorable clinical course and prognosis. Members of this
class include isotretinoin and etretinate. It is estimated that
60–95% of patients will have clinical improvement within
6 months of starting therapy (Cohen and Prystowsky,
1989). Methotrexate has traditionally been a good second
line treatment (Caplan et al., 1997). Other cytotoxic and
immunosuppressive medications, such as azathioprine and
cyclosporine A, has been cited in the literature as
successful modalities (Caplan et al., 1997). Steroids
appear to be effective but unpractical for long term use.
Less conventional regimens include vitamin C and E,
often used in combination with vitamin A, isoniazid,
paraaminosalicyclic acid, penicillin, hydroxychloroquine,
arsenic, pilocarpine, pituitary extract, foreign protein
injections, and topical 6-aminonicotinamide (Cohen and
Prystowsky, 1989).
CONCLUSION
In summary, PRP is an extremely rare skin disorder. It is a
member of the hyperkeratotic, papulosquamous diseases.
There have been case reports citing rheumatologic
associations, mainly arthritis and dermatomyositis.
However, it is difﬁcult to establish the precise rheuma-
tologic association of PRP given the rarity of this disease.
To really establish a relationship, there needs to be a large
prospective study.
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